A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

NCT04856930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

BIOLOGICAL: Imsidolimab
BIOLOGICAL: Placebo

Sponsor

Vanda Pharmaceuticals